Ignite Creation Date:
2025-12-24 @ 6:44 PM
Ignite Modification Date:
2025-12-27 @ 10:19 PM
Study NCT ID:
NCT01805557
Status:
COMPLETED
Last Update Posted:
2022-06-08
First Post:
2013-03-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-02-04
Start Date Type:
ACTUAL
Primary Completion Date:
2019-03-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-11-20
Completion Date Type:
ACTUAL
First Submit Date:
2013-03-05
First Submit QC Date:
None
Study First Post Date:
2013-03-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-06-06
Last Update Post Date:
2022-06-08
Last Update Post Date Type:
ACTUAL